TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| TriSalus Life Sciences, Inc. | ||
| By: | /s/ David Patience | |
| Name: | David Patience | |
| Title: | Chief Financial Officer | |
| Date: | March 5, 2026 | |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mary Szela and David Patience, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Mary Szela | Chief Executive Officer and Director(Principal Executive Officer) | March 5, 2026 |
| Mary Szela | ||
| /s/ David Patience | Chief Financial Officer(Principal Financial and Accounting Officer) | March 5, 2026 |
| David Patience | ||
| /s/ Mats Wahlström | Director and Chairman of the Board | March 5, 2026 |
| Mats Wahlström | ||
| /s/ Michael P. Stansky | Director | March 5, 2026 |
| Michael P. Stansky | ||
| /s/ Gary Gordon | Director | March 5, 2026 |
| Gary Gordon | ||
| /s/ Kerry Hicks | Director | March 5, 2026 |
| Kerry Hicks | ||
| /s/ David J. Matlin | Director | March 5, 2026 |
| David J. Matlin | ||
| /s/ William Valle | Director | March 5, 2026 |
| William Valle | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.